Shanghai Fosun Pharmaceutical's (SHA:600196, HKG:2196) drug registration application for the Fovinaciclib citrate capsules by unit Jinzhou Avanc Pharmaceutical, has been accepted by China's National Medical Products Administration, a Thursday bourse filing said.

The indication under the application is locally advanced or metastatic breast cancer, where the drug should be used in combination with an aromatase inhibitor as initial endocrine therapy for premenopausal, postmenopausal, and perimenopausal female patients with breast cancer.